The two companies want to develop better delivery models for psilocybin treatment. The post Compass Pathways, Journey Clinical to develop psilocybin treatment...
LONDON, April 29, 2024 (GLOBE NEWSWIRE) — Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient...
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing...
The new company will be called "Tryptamine Therapeutics Limited," and will trade on the ASX under the ticker symbol "TYP". The post Tryp Therapeutics,...
VANCOUVER – MindBio Therapeutics Corp. (CSE: MBIO) (Frankfurt: WF6), (the ‘Company’ or ‘MindBio’), a clinical stage biopharma company uniquely...
VANCOUVER, British Columbia, April 24, 2024 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT:...
NEW YORK and BERLIN, April 24, 2024 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical...
The new company will be called "Tryptamine Therapeutics Limited," and will trade on the ASX under the ticker symbol "TYP". The post Tryp Therapeutics merger...
SARASOTA, FL, April 23, 2024 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical...
SARASOTA, FL, April 23, 2024 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical...